Connected Pens for Diabetes Study

Not Applicable

Terminated

• Conditions: Diabetes Mellitus
• Interventions: Device: Connected insulin pen and smartphone app; Device: Inactive connected insulin pen without smartphone app

• Registration Number: NCT03830216
• Lead Sponsor: Companion Medical, Inc.

Brief Summary

The objective of the study is to evaluate the impact of a wireless smart insulin pen and smartphone-based bolus advisor on clinical and psychosocial outcomes in insulin-treated diabetes mellitus patients after 3 months of use.

Detailed Description

The study is a prospective, randomized, controlled treatment design. The study device will be used for multiple daily injection (MDI) therapy of insulin. The participant will interact with the study device in the uncontrolled environment of the participant's daily life. The study protocol is designed to yield meaningful data to determine clinical and psychosocial benefits of using the study device. The study will evaluate the study device as an intervention versus a control group.

Study Timeline

• Study First Submitted: 2019-01-30
• Study First Submitted QC: 2019-02-01
• Study First Posted: 2019-02-05
• Study Start: 2019-05-30
• Primary Completion: 2019-11-12
• Study Completion: 2019-11-12
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-25
• Last Update Posted: 2021-01-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

1. The participant is ≥ 18 years of age
2. The participant has Type 1 OR Type 2 diabetes and is being treated with intensive insulin therapy via injection for ≥ 3 months. Intensive insulin therapy is defined as at least one long acting insulin dose and two or more short acting insulin doses per day.
3. Glycated hemoglobin (HbA1c) ≥ 7.5%).
4. The participant is a current iPhone user for over 30 days.
5. Participant adjusts meal insulin doses based on carbohydrate content of meals.
6. The participant is fluent in the English language.
7. The participant and the investigator understand participant obligations and agree that the participant is willing and able to complete the study visits.
8. Patients prandial insulin need must be <30 U per meal.

Exclusion Criteria

1. The participant has been using unblinded CGM for less than 6 months.
2. The participant uses pre-mixed insulin.
3. Current use of a smart insulin pen.
4. Use of sliding scale insulin therapy that determines insulin dosages based exclusively on specific blood glucose results
5. Used systemic oral or inhaled steroids for more than 7 days within the last 3 months
6. Oral anti-diabetic agents, with the exception of metformin
7. Injectable anti-diabetic agents other than insulin
8. The participant is legally blind or has below specified best-corrected vision level.
9. Diagnosed with any clinically significant infectious disease or major organ system disease, such as gastroparesis or renal disease (at Investigator's discretion)
10. The participant is pregnant, lactating, or plans to become pregnant in the next 6 months.
11. The participant is currently participating in another clinical study that may preclude the participant from meeting the obligations of this study.
12. The participant has any additional condition(s) (medical, social, or psychosocial) that in the investigator's opinion would warrant exclusion from the study or prevent the participant from completing or complying with the study requirements.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment Arm	Connected insulin pen and smartphone app	Study subjects will administer prandial insulin to manage their diabetes using a connected insulin pen and smartphone app with integrated dose calculator.
Control Arm	Inactive connected insulin pen without smartphone app	Study subjects will administer prandial insulin to manage their diabetes using an inactive connected insulin pen without smartphone app.

Primary Outcome Measures

Name	Time	Method
CGM time in range	3 months	Percent CGM time in range (70-180 mg/dL) at 90 days, measured over 14 day period

Secondary Outcome Measures

Name	Time	Method
Change in patient reported outcomes - DTSQ	3 months	The Diabetes Treatment Satisfaction Questionnaire (DTSQ) measures diabetes treatment satisfaction. The 8 items measure treatment satisfaction and perceived frequency of hyperglycemia and hypoglycemia.
Change in patient reported outcomes - IDSS	3 months	The Insulin Delivery Satisfaction Survey (IDSS) measures insulin delivery device satisfaction. The 14 items measure provides a comprehensive profile of sources of device satisfaction.
Change in patient reported outcomes - HCS	3 months	The Hypoglycemic Confidence Scale (HCS) Hypoglycemic measures the degree to which patients feel able, secure, and comfortable regarding their ability to avoid hypoglycemia.
Absolute change in HbA1c	3 months	Average change in HbA1c from Baseline to Month 3 compared between groups
Mean sensor glucose (mg/dL)	3 months	Mean sensor glucose will be measured on the final blinded, professional CGM session performed at the end of the 3 month
Percent CGM time spent in hypoglycemia (70-54 mg/dl, < 54 mg/dL)	3 months	Percent of time spent in hypoglycemia from Baseline to Month 3 will be compared between groups
Percent CGM time spent in hyperglycemic range (>180 mg/dl, >250 mg/dL)	3 months	Percent of time spent in hyperglycemia from Baseline to Month 3 will be compared between groups
Change in patient reported outcomes - ADDQoL	3 months	The Audit of Diabetes Dependent Quality of Life (ADDQoL) Questionnaire measures diabetes-specific quality of life. The 19 items measure the impact of diabetes on specific aspects of life and the importance of these aspects of life for quality of life.

Trial Locations

Locations (1)

Mary & Dick Allen Diabetes Center, Hoag Memorial Hospital Presbyterian; 🇺🇸 Newport Beach, California, United States